CAS 55726-47-1|Enocitabine

Introduction：Basic information about CAS 55726-47-1|Enocitabine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Enocitabine BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Synonyms

Common Name	Enocitabine
CAS Number	55726-47-1	Molecular Weight	565.785
Density	1.2±0.1 g/cm3	Boiling Point	/
Molecular Formula	C₃₁H₅₅N₃O₆	Melting Point	141-142ºC
MSDS	/	Flash Point	/

Names

Name	Enocitabine
Synonym	More Synonyms

Enocitabine BiologicalActivity

Description	Enocitabine, a nucleoside analog, is a potent DNA replication inhibitor and a DNA chain terminator. Enocitabine can be used as an effective chemotherapeutic agent for the treatment of acute myelogenous leukaemia and lymphocytic leukaemias[1].
Related Catalog	Research Areas >>CancerResearch Areas >>InfectionSignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogSignaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA SynthesisSignaling Pathways >>Anti-infection >>CMV
Target	DNA replication[1]; CMV[3]
In Vitro	Enocitabine is resistant to deamination because Enocitabine bears a highly lipophilic group at the 4-amino position of the cytosine moiety of cytarabine[1]. The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells[2]. In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed[3].
References	[1]. Hamada A, et al. Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet. 2002;41(10):705-18. [2]. Nagasawa M, et al.In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines. Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 1):633-8. [3]. Nakamura K, et al. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990 Jun;31(2):141-7.

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Melting Point	141-142ºC
Molecular Formula	C₃₁H₅₅N₃O₆
Molecular Weight	565.785
Exact Mass	565.409058
PSA	133.91000
LogP	9.00
Index of Refraction	1.554
InChIKey	SAMRUMKYXPVKPA-VFKOLLTISA-N
SMILES	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1
Storage condition	-20°C Freezer

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: JR1230400

CHEMICAL NAME :: Docosanamide, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyri midinyl)-

CAS REGISTRY NUMBER :: 55726-47-1

LAST UPDATED :: 199612

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C31-H55-N3-O6

MOLECULAR WEIGHT :: 565.89

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >1 gm/kg

TOXIC EFFECTS :: Blood - other changes

REFERENCE :: YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 25,691,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: GTKRDX Gan to Kagaku Ryoho. Cancer and Chemotherapy. (1-8-9 Yaesu, Chuo-ku, Tokyo 103, Japan) V.1- 1974- Volume(issue)/page/year: 10,2077,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >1352 mg/kg

TOXIC EFFECTS :: Blood - other changes

REFERENCE :: YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 25,691,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 380 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 14,484,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >1500 mg/kg

TOXIC EFFECTS :: Blood - other changes

REFERENCE :: YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 25,691,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 525 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 14,484,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 810 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: GTKRDX Gan to Kagaku Ryoho. Cancer and Chemotherapy. (1-8-9 Yaesu, Chuo-ku, Tokyo 103, Japan) V.1- 1974- Volume(issue)/page/year: 10,2077,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 14,484,1983

Safety Information

Hazard Codes	Xi

Synonyms

1-(β-D-Arabinofuranosyl)-4-(docosanoylamino)pyrimidin-2(1H)-one

ENOCITABINE ANTINEOPLASTIC DRUGS

N(4)-Behenoyl-1-b-D-arabinofuranosylcytosine

BH-AC

n(sup4)-behenoylcytosinearabinoside

1-(β-D-Arabinofuranosyl)-4-(docosanoylamino)-2(1H)-pyrimidinone

BEHENOYLCYTOSINE ARABINOSIDE

MFCD00866294

Docosanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-

Enocitabine

Sunrabin

2(1H)-Pyrimidinone, 1-β-D-arabinofuranosyl-4-[(1-oxodocosyl)amino]-

N-(1-b-D-Arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)docosanamide

Enocitabine [INN:JAN]

N4-Behenoylcytosine arabinoside

Recommended......